WCA
RXST icon

Westover Capital Advisors’s RxSight RXST Stock Holding History

Westover Capital Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,589
Closed -$457K – 252
2024
Q2 		$457K Buy
+7,589
New +$434K 0.12% 138

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Westover Capital Advisors's RXST Position: Q3 2024 in Review

Westover Capital Advisors sold out of RxSight (RXST) in Q3 2024, closing a stake of 7,589 shares — an estimated $457K sold.

Westover Capital Advisors first reported a position in RXST in Q2 2024 and held it in 1 quarter. The position peaked at $457K in Q2 2024. 214 funds tracked by Wall St. Rank hold RXST as of Q3 2024.

  • Westover Capital Advisors reported no remaining RxSight position as of Q3 2024 after selling out during the quarter.
  • Westover Capital Advisors sold 7,589 RxSight shares in Q3 2024, an estimated $457K.
  • Westover Capital Advisors first reported a position in RxSight in Q2 2024 and held it in 1 quarter.
  • Westover Capital Advisors's RxSight position peaked at $457K in Q2 2024.
  • 214 funds tracked by Wall St. Rank held RxSight as of Q3 2024.

Based on Westover Capital Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.